Pipeline
Cullinan is advancing a broad and deep pipeline of eight targeted oncology programs that span a range of cancer indications and diverse technology platforms at various stages of development. Our focus is on first- and/or best-in-class potential molecules that activate the immune system or target key oncogenic drivers with the promise of single agent efficacy.
| Program (Subsidiary/Project) Modality / MOA |
Discovery / Lead Optimization | IND-Enabling | Phase 1 | Phase 2 | Phase 3 | Status |
| CLN-081 (Pearl) EGFR ex20 inhibitor |
NSCLC with exon 20 insertion mutations |
BTD received; Regulatory update Q1 ’22 | ||||
| CLN-049 (Florentine) FLT3 x CD3 bispecific |
R/R AML |
Clinical trial initiated Dec 2021 | ||||
| CLN-619 (MICA) Anti-MICA/B IgG1 |
Pan-cancer |
Clinical trial initiated Dec 2021 | ||||
| CLN-617 (Amber) Collagen-binding IL12-IL2 fusion protein |
Pan-cancer |
IND-enabling studies | ||||
| CLN-978 (NexGem) CD19 X CD3 X HSA trispecific |
B-cell ALL, NHL |
IND-enabling studies | ||||
| Jade TCR-based therapy targeting a senescence and cancer-related protein pMHC complex |
HPV+/RB- |
IND-enabling studies | ||||
| Opal PD-1 x CD137L fusion protein |
Pan-cancer |
Candidate selection | ||||
| HPK1 Potentially first-in-class protein degrader |
Pan-cancer |
Candidate selection | ||||